These are the highlights of Lupin for the quarter ending September 30, 2025. Financial Highlights – Consolidated IND-AS

• Gross Profit was ? 50,066 million compared to ? 38,071 million in Q2 FY2025, with a gross margin of 73.3%.
• Personnel cost was 16.2% of sales at ? 11,056 million compared to ? 10,075 million in Q2 FY2025.
• Manufacturing and other expenses were 29.0% of sales at ? 19,796 million compared to ? 16,670 million in Q2 FY2025.
• PBT at ? 20,070 million at 29.4%, up 90.3% YoY from ? 10,549 million in Q2 FY2025.
• Investment in R&D for the quarter was ? 5,091 million (7.5% of sales).

Balance Sheet highlights

• Operating working capital was ? 77,304 million as on September 30, 2025.
• Capital Expenditure for the quarter was ? 3,474 million
• Net Debt as on September 30, 2025, stands at ? 16,646 million
• Net Debt Equity as on September 30, 2025, stands at -0.08.

Mr. Nilesh Gupta, Managing Director, Lupin Limited said “We are delighted to present one of our strongest performances ever in this second quarter of FY26. We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the U.S., emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong FY26”.

Lupin is a global pharmaceutical company from India, advancing healthcare through innovation, research and accessible medicines globally.